by Stu Steene-Connelly | Jul 3, 2024 | Patient Empowerment
When PrismRA can help guide treatment decisions: intended use & case study examples For patients with rheumatoid arthritis (RA), ineffective early treatment increases the likelihood of surgery, irreversible joint damage, and chronic pain.1 Prior to PrismRA,...
by Stu Steene-Connelly | Jun 15, 2024 | Science & Technology
PrismRA Was Developed & Clinically Validated to Guide RA Therapy Selection PrismRA® is a blood-based precision medicine test that was developed using the science of the human interactome to help guide the treatment of rheumatoid arthritis. The human interactome is...
by Stu Steene-Connelly | May 15, 2024 | Patient Empowerment, Science & Technology
Examining the Clinical Utility of PrismRA PrismRA® is a blood-based precision medicine test used by over 1,400 advanced practitioners around the country to guide the treatment selection in their patients with rheumatoid arthritis. While validated precision medicine...
by Stu Steene-Connelly | Apr 30, 2024 | Science & Technology
Current Care Therapy Selection for RA Relies on Trial-and-Error Rheumatoid arthritis (RA) affects roughly 1.6 million people in the US and as much as 1% of the population worldwide.1 This chronic autoimmune disease attacks the lining of the joints on both sides of the...
